CLASSIFICATION OF END-STAGE LIVER DISEASE AND PROGNOSIS
Cirrhosis is classified into two stages compensated and decompensated. This classification is simple and reproducible and identifies patients at a similar rate of disease progression and survival. Decompensated cirrhosis is defined by the presence of ascites, variceal bleeding, encephalopathy and/or jaundice. 4, 9 Transition from a compensated to a decompensated stage occurs at a rate of 5-7% per year. 10 In fact, it is well known that life expectancies in compensated and decompensated cirrhosis are strikingly different and it is, therefore, conceivable that prognostic indicators may be different or may have a different weight according to the disease stage. 11 And, Child-Pugh score and MELD score may be unsatisfactory when applied separately to compensated and decompensated patients. 11 Recent systemic review found the Child-Pugh score was still most significant among the predictors of death despite the absence of ascites, encephalopathy and jaundice in the patients with compensated cirrhosis, because its laboratory components, bilirubin, albumin and prothrombin time continued to be among the most frequent predictors, indicating that even subtle abnormalities in these laboratory parameters are predictive of death. 8 In addition to these markers of liver insufficiency, in the compensated stage, significant predictors that come to light are those related to portal hypertension, such as the presence of varices, splenomegaly and platelet count as well as gamma-globulin levels (as hyper gamma-globulinemia is an indirect marker of portosystemic shunting). This probably indicates that, in a compensated stage, measurements of portal pressure will be of important prognostic value. This is strengthened by a recent study in which the most important predictor of the development of varices was a hepatic venous pressure gradient (HVPG) of >10 mmHg in patients with stage 1 liver cirrhosis (no varices and no ascites). Conversely, the set of significant prognostic variables in the group of patients with decompensated cirrhosis reflect a more advanced stage, as bleeding and hepatocellular carcinoma (HCC) become predictive of death. It is in this group that the Child-Pugh score (and its components) has the most important prognostic value. In addition to the Child-Pugh score, parameters that reflect a further deterioration of the circulatory status of the cirrhotic patient, such as parameters of renal dysfunction (creatinine and blood urea nitrogen) arise as powerful prognostic indicators in this setting and, therefore, it is not surprising that the MELD score (which incorporates creatinine in addition to markers of liver dysfunction) has become a valuable method to allocate organs. On the contrary, it is predictable that the MELD score would not be useful to predict survival in patients with compensated cirrhosis.
From the clinical point of view, it will be important to assess prognostic variables separately for the different stages of cirrhosis, at a minimum, separating those with compensated and those with decompensated cirrhosis. In patients with decompensated cirrhosis, any study of predictors of death should include important variables identified by the majority of studies, such as the Child-Pugh score (or its components) and age. In patients with compensated cirrhosis (or status 1 and 2), particularly in those who remain at a compensated stage, the risk of dying is low and in this group of patients it would be more useful to look at predictors of decompensation rather than at predictors of mortality.
CHILD-PUGH SCORE, ITS APPLICATION AND LIMITATION
Child-Pugh score has been the reference for more than 30 years for assessing the prognosis of cirrhosis. At the bedside, Child-Pugh score is widely used as a simple descriptive or prognostic indicator and is frequently associated to other indicators. Initially, the Child score included two laboratory variables (bilirubin and albumin) and there quantitative variables (ascites, encephalopathy and nutritional status). The five variables were arranged so as to define their groups of severity (A, B and C). 1 It was originally designed for predicting the outcome after surgery for portal hypertension (portocaval shunting) in patients with cirrhosis. Child-Pugh score, a modified version, proposed 10 years later. 2 The only change in this modified version was that nutritional status was replaced by prothrombin time. In previously reported studies, the variation in survival explained by Child-Pugh score remains somewhat low (less than 50%), as it is the case with most survival models 12 emphasizing the fact that other factors play an important role in prognosis.
In recent large systematic review, the most consistent and 'robust' predictor of death in cirrhosis is the Child-Pugh score. And, this was followed by its all components (albumin, bilirubin, ascites, encephalopathy and prothrombin time). Finally, it does not include a measure of renal function, which is a well-established prognostic marker in cirrhosis.
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MELD SCORE, ITS APPLICATION, DERIVATIVES AND LIMITATION
While Child score was originally designed for assessing the prognosis of cirrhotic patients undergoing surgical treatment of portal hypertension, MELD was initially created to predict survival following elective placement of TIPS. 18 Before February 2002 in the US, transplant candidates were prioritized to receive organs for liver transplantation based on the United Network of Organ Sharing (UNOS) status that primarily reflected their CTP scores. In a prospective study of candidates on the waiting list, MELD was an excellent predictor of waiting-list mortality. 19 In this study, the MELD scoring system was shown to predict 3-month mortality more accurately than the traditional CTP system for patients with UNOS statuses of 2A (CTP score >10 plus cirrhosis-related complications such as active variceal haemorrhage, hepatorenal syndrome, refractory ascites/hepatic hydrothorax or stage 3 or 4 HE) and 2B (CTP score >10, or score >7 plus complications) patients. 19 The "c" statistic represents a global estimate of the ability of a score to predict an event. This statistic, which is derived from the area under the receiver operating characteristic curve, ranges from 0 to 1. A "c" statistic of 0.5 means that the score is of no value for predicting a given event. A "c" statistic of 1 means that the score is perfect. A c-statistic of 0.7 is thought to have reasonable clinical utility, while a c-statistic of >0.8 in a prediction model lends strong support to its accuracy. The concordance (c-statistic), with 3-month mortality as the end point, for the MELD score was 0.83 indicating that when a pair of patients is randomly drawn out of the study population, 83% of the time the model correctly predicts the first patient to die. 20 Most studies that evaluated MELD to rank patients according to their risk of mortality have yielded "c"-statistics upwards of 0.8, and usually superior to the CTP class.
In February 2002 the MELD score was adopted as the basis for allocation of allografts for liver transplantation (LT) in the United States. According to the MELD-based policy, patients with the highest score have a priority for organ allocation. 21 More recently, MELD score has also been adopted in several European countries as well as in South America.
COMPONENTS OF THE MELD SCORE
MELD incorporates 3 widely available laboratory variables including the international normalized ratio (INR), serum creatinine, and serum bilirubin. The original mathematical formula for MELD is: MELD 0.957×log (creatinine)+0.378×log (total bilirubin)+1.120 log (INR)+0.6431. The score can be calculated on handheld computing devices, and is available at www.mayoclinic.org/gi-rst/ mayomodel5.html. To lessen the influence of extreme values, the natural logarithm of bilirubin INR and creatinine were entered into the model.
Creatinine
It is common to see a substantial degree of variability in renal function in patients with end-stage liver disease. More importantly, diminished renal function is an important predictor of survival in those patients. [22] [23] [24] [25] Serum creatinine has a sigmoid pattern in that the increase in mortality is linear within a range of creatinine, in partial support of the current lower and upper bounds of 1 and 4, respectively. however, substantial changes in serum creatinine may occur, especially in those undergoing large-volume paracentesis and/or receiving diuretics. Laboratory methods may also interfere with the value of serum creatinine. To measure serum creatinine level, O'Leary modified Jaffe, compensated kinetic Jaffe, enzymatic and standard kinetic Jaffe methods have been used and compared in the calculation of the MELD score. There is a poor agreement among different creatinine assays, especially as serum bilirubin rises. 26 Accordingly, the new standard is an enzymatic method for measuring serum creatinine. And, accuracy of noninvasive measurement of renal function, including serum creatinine, has been shown to be suboptimal among cirrhotic patients. [27] [28] [29] Measured glomerular filtration rate (GFR) is better at assessing prognosis than creatinine and mathematical equations containing creatinine. 27, 28 A multivariable model that incorporates calculated GFR and/or serum sodium is superior to the MELD score.
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Billirubin
Serum bilirubin concentration is a well established marker of the hepatic synthetic function, although it represents excretory function. Of the 3 MELD variables, serum total bilirubin is the most important. It has a linear relationship with 90-day mortality in patients waiting for LT. 30 
INR
Prothrombin time and the INR reflect coagulopathy associated with synthetic dysfunction in patients with end-stage liver disease. After adjusting for bilirubin and creatinine, INR is associated with a steep increase in mortality risk. However, once it reaches approximately 3, the risk does not seem to increase any further. However, there are some limitations. First, it has been shown that interlaboratory variation in INR is ~25%. Among the three variables of MELD score, INR has the highest multiplicative value. Therefore variations in INR may translate to up to 20% differences in MELD score. 31 Second, when applied to individuals with liver disease, this method of calculation for INR proves to be suboptimal. 31, 32 Because, INR was designed to standardize the anticoagulation effect of warfarin and not to evaluate the severity of liver disease. As a result, INR may not be valid to assess liver impairment. 33, 34 In studies in which plasma samples of patients with liver disease were tested using different prothrombin reagents, there was a substantial degree of variation in INR values. 35, 36 In contrast, if calibration is done using standards derived for patients with liver disease, interassay and interlaboratory variability could be reduced significantly.
Despite of several limitations of INR, INR remains a practically useful and statistically significant correlate of mortality risk in patients with end-stage liver disease. 37 It is also widely available and is likely continue to be used as an indicator of survival in patients with end-stage liver disease and as a component of the MELD score.
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MELD APPLICATION
In comparison with the CTP system, recent studies suggested that the MELD may more accurately predict the survival for patients with cirrhosis. 38, 39 However, other studies reported different results, showing that the MELD was not necessarily better than the CTP system. A recent systemic review showed that of the 11 studies, only four studies (4,512 patients) demonstrated a statistical superiority of the MELD in comparison with the CTP system, whereas seven studies (8,020 patients) showed no statistical difference. There have been no satisfactory explanations for these discordant results. A possible reason could be that lower range MELD scores may have a less accurate predictive ability. The MELD score, as an objective scale of disease severity, has been used in the management of patients with chronic liver disease in the non-transplant setting as below.
Further, the MELD score has been used in the management of patients with a wide spectrum of liver disease including alcoholic cirrhosis and alcoholic hepatitis.
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MELD AND COMPLICATION OF CIRRHOSIS
MELD score also proved to be a reliable marker of 1-year and 5-year survival across a broad spectrum of liver diseases including alcoholic cirrhosis and alcoholic hepatitis. 13 In addition, MELD score has been shown to be a good prognostic marker in cases of variceal bleeding, 40 spontaneous bacterial peritonitis, and hepatorenal syndrome (HRS). In patients with variceal bleeding, the cstatistic for in-hospital and 1-year mortality was 0.83 (0.74-0.92) for MELD and 0.78 (0.69-0.87) for CTP without statistical difference. In the study of HRS, all patients with type 1 HRS had a high MELD score (>20) and showed an extremely poor outcome (median survival: 1 mo HRS was longer and dependent on MELD score (>20, median survival 3 mo; <20, median survival 11 mo; P<0.002). 41 However, the MELD score does not include HE and MELD score is far less sensitive in reflecting the presence or severity of HE. MELD scores did not show any correlation with clinical or subclinical HE. 42 Other study showed that HE, MELD and CTP scores were the only factors associated independently with short-and long-term mortality in cirrhotic patients. 13 The MELD score underestimates the risk of death in patients with end-stage liver disease and intractable HE 43 or acute on chronic liver disease who developed HE. 44 Ascites and/ or low serum Na, as manifestations of advanced haemodynamic derangement of cirrhosis, were found to associate significantly with mortality on the transplantation list. In multivariate analysis MELD score, persistent ascites and low Na (<130 mmol) were the only factors independently associated with 6-month mortality. Although MELD score was the only predictor of 6-month mortality in the subgroup of patients with advanced liver disease (MELD score: ≥21), only ascites and hyponatremia (as a continuous or categorical variable using a cut-off of the lower limit of normal of 135 mmol) were independent factors associated with 6-month mortality in patients with less severe liver disease (MELD score: <21). In several studies, it was confirmed that the etiology of cirrhosis was a less important variable in determining survival in other patient cohorts with end-stage liver disease. Therefore, etiology of liver disease was removed as a variable from the model. The advantage of dropping etiology of cirrhosis as a variable was that the subjective element in determining etiology was removed, and the model could be based purely on objective laboratory variables.
MELD AND ALCOHOLIC HEPATITIS
In severe alcoholic hepatitis has been defined by a "discriminant function" above 32. 45 In addition to this discriminant function, generally termed as "Maddrey score" (or Maddrey discriminant function), several specific scores have been created to predict early mortality in patients with severe alcoholic hepatitis. 46, 47 The more general MELD score has also been assessed in this setting. MELD score proved to be as efficacious as or even superior to the original Maddrey discriminant function. This finding is not surprising since MELD score includes the two variables (bilirubin and prothrombin time) included in the Maddrey discriminant function.
MELD AND PRIMARY BILIARY CIRRHOSIS (PBC)
PBC is one of the causes of cirrhosis for which specific prognostic scores were first proposed. 48, 49 The aim of scoring was to determine the optimal timing for transplantation. Even though specific scores exist for PBC, there is no evidence that patients with PBC are misclassified with MELD score. Nor there is evidence that specific scores are superior to MELD. However, no discriminant value of MELD score has been established to specifically identify PBC patients who may benefit from transplantation.
MELD AND PRIMARY SCLEROSING CHOLANGI-TIS (PSC)
The course of PSC is much more variable than that of PBC. Therefore, it is more difficult to create reliable prognostic scores, especially for assessing long-term outcome. MELD score has not been specifically assessed for PSC. However, most patients with advanced PSC have high bilirubin level. In these patients, it is unlikely that disease severity is underestimated by MELD score compared with other chronic liver diseases.
MELD AND ICU SETTING
In the particular setting of ICU, it can be reasonably assumed that Child-Pugh and MELD score have significant limitations for predicting very short-term survival. Previous study showed that cirrhotics admitted to ICU with three or more failing organ systems have 90% mortality and that SOFA (Sequential Organ Failure Assessment) and MELD were better predictors than APACHE II or Child-Pugh scores.
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MELD AND HEPATOCELLULAR CARCINOMA
The MELD has been suggested to be incorporated into the staging system for hepatocellular carcinoma (HCC) to replace the CTP system. Mayo group showed that neither minor hepatic resections (≤3 segment resection) nor major resection (≤4 segment) were associated with any mortality 30 days postoperatively if MELD score was ≤8. Moreover, patients with HCC smaller than 5 cm in diameter and MELD score ≤8, had a 5-year survival of 80%. 51 Studies showed that the modified staging systems had an in-http://www.e-cmh.org http://dx.doi.org/10.3350/cmh.2013.19.2.105 creased predictive accuracy in comparison with the original staging systems for HCC. 52, 53 These findings implicate that although the MELD was originally created to study the 3-month survival in cirrhotic patients, it can also be used to predict the long-term outcome of HCC.
MELD AND NONTRANSPLANT SURGERY
Child-Pugh score has been used for predicting the setting of nontransplant surgery. The MELD score has also been shown to be a useful model in predicting the outcomes in cirrhotic patients undergoing major surgical procedures. [54] [55] [56] In general, there is approximately a 1% increase in mortality risk per MELD point below a score of 20. There is a 2% increase in mortality risk per MELD point over 20. 57 Mortality is higher for intra-abdominal surgery (up to 25%) compared with other types of surgery. The c statistic of the MELD score for predicting 30-day mortality was found to be 0.72 in the whole population of patients undergoing surgery and 0.8 in the subgroup with intra-abdominal surgery. However, there are no simple limits with MELD score such as Child-Pugh grades A, B, and C for estimating patients' risk. This algorithms based on MELD score for different types of surgery would be helpful to replace Child-Pugh score.
MODIFYING MELD
The outcome of cirrhosis is quite variable from patient to patient according to different causes, different stages, and different therapeutic options. And, with the expansion of MELD score, several "MELD exceptions" emerged. Therefore, several models have been proposed to refine and improve the MELD score. As many as 11 different scores are available for addressing general or more specific issues regarding the prognosis of cirrhosis (Tables 1, 2) .
MELD NA
Cirrhotic patients often have dilutional hyponatraemia because of altered vascular haemodynamics. Systemic arterial vasodilation leads to the release of antidiuretic hormone which, in turn, induces dilution hyponatremia. The activation of these mechanisms correlates with the degree of portal hypertension. 58 In this view, hyponatremia can be considered an indirect marker of portal hypertension during cirrhosis. Notably, profound hyponatraemia is frequently associated with severe complications in liver cirrhosis, including ascites, hepatorenal syndrome and liver related mortality 15, [59] [60] [61] [62] and is associated with neurologic dysfunction, refractory ascites, hepatorenal syndrome, and death from liver disease. 63, 64 Therefore, hyponatremia, with lower sodium values predicting worse outcomes, has been shown to be an independent predictor 66 Several studies have shown that hyponatremia is a strong predictor of early mortality, independent of MELD score. [66] [67] [68] After controlling for MELD, serum sodium was associated with a higher risk of mortality: each 1 mmol/L decrease in the serum sodium concentration for values between 125 and 140 mmol/L was associated with 5% increase in mortality (P<0.001). 65 Changes in survival are especially pronounced for sodium concentrations ranging from 120 to 135 mEq/L. Within this range, a decrease in serum sodium of 1 mEq/L corresponds to a 12% decrease in 3-month probability of survival. 66 A modified score including serum sodium, termed MELD-Na, has been proposed as an alternative to MELD score (Table 1) . [66] [67] [68] The addition of Na to the MELD improves its predictive accuracy, especially for patients with lower range MELD scores. As reported in most studies, when the MELD score increases, serum Na contributes much less to increasing mortality prediction. 69, 70 However, the addition of serum Na did not significantly improve the accuracy of the MELD score in the prediction of survival at 3 and 12 months. A limitation to the addition of serum sodium into MELD is that during cirrhosis, marked changes in serum sodium concentration can result from several factors, including the administration of diuretics and intravenous hypotonic fluids. 71 In contrast, the use of V2-receptor antagonists for treating refractory ascites induce a significant increase in serum sodium. Again, serum sodium is not as objective as it was thought to be. In summary, the contribution of hyponatraemia to outcome prediction is possible only under a specific clinical setting (such as a low MELD score) rather than a direct linear relationship.
DELTA MELD
Another concern of the MELD is whether a single point determination of the score can adequately differentiate the degree of urgency for transplantation. The usefulness of a change in MELD (delta MELD) in predicting waiting-list mortality has been studied with different results. 39, [72] [73] [74] In recent systematic review, delta MELD was reported to predict more accurately the survival in cirrhotic patients awaiting liver transplantation. 75 However, the prognostic value of delta MELD has not been confirmed in another study and may require further investigations. 72 The increase in MELD is confounded by (1) patients with a sharp increase in MELD tending to have a high MELD score currently, and (2) in retrospective analysis, patients who are acutely worsening have frequent laboratory testing, which may represent the clinician's clinical judgment of the worsening patient's condition.
MELD AND PROGNOSIS ACCORDING TO COM-PLICATION OF PORTAL HYPERTENSION
Studies showed that individual complications of portal hypertension, such as spontaneous bacterial peritonitis, encephalopathy, variceal bleeding, or ascites, did not provide further prognostic information when added to MELD.
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LIMITATION OF MELD
First, on the basis of variables, they initially, were also selected empirically because they were felt to have a potential prognostic influence. Therefore, it cannot be excluded that some important variables have not been taken into account for analysis. 76 Second, another limitation comes from the absence of clear-cut discriminant values with MELD score. Such discriminant limits with MELD score have not yet been determined in a broad scope of situations.
Third is come from that some important prognostic predictors, such as intractable hepatic encephalopathy, oesophageal variceal bleeding and spontaneous bacterial peritonitis, which are common adverse complications in cirrhosis, are not included in the MELD. Fourth, one must remember that MELD was created and validated in a cohort of patients who were absent of acute, reversible complications, such as bacterial infection or azotemia. Therefore, in patients on the waiting list for liver transplantation, the MELD score should be calculated only after acute reversible processes are adequately treated.
Finally, depending on the population to which MELD is applied, mortality seen in patients with a given MELD score may not necessarily be the same. Similarly, hospitalized patients with cirrhosis who were not candidates for liver transplantation may have a higher mortality than candidates for liver transplantation who are younger and devoid of comorbidity. Thus, it is not possible to provide a universally applicable survival prediction by MELD. 
CONCLUSION
In recent years, MELD score emerged as a "modern" alternative to Child-Pugh score.
It is still not clear, whether MELD is better than CTP score for predicting survival in patients with chronic liver disease outside of liver transplant waiting lists. However, MELD score has several strengths compared with Child-Pugh score. The variables incorporated into the MELD score are simple and more objective. The weight of each variable has been determined by statistical analysis. MELD is a continuous score, which makes it more convenient for scoring individuals within large populations. In addition to organ allocation, the MELD score has been an important contribution to hepatology given its ability to accurately gauge the severity of liver disease and effectively assess the risk of mortality. By design, it is continually evolving; it lends itself to continued refinement and improvement in a data-driven fashion. All these reasons make the MELD score likely to be the core tool for assessing the prognosis of cirrhosis in the future.
